Cargando…
The p53-dependent apoptotic pathway of breast cancer cells (BC-M1) induced by the bis-type bioreductive compound aziridinylnaphthoquinone
INTRODUCTION: Several aziridinylbenzoquinone drugs have undergone clinical trials as potential antitumor drugs. These bioreductive compounds are designed to kill cells preferentially within the hypoxia tumor microenvironment. The bioreductive compound of bis-type naphthoquinone synthesized in our la...
Autores principales: | Yang, Yu-Ping, Kuo, Hsien-Shou, Tsai, Hsin-Da, Peng, Yi-Chen, Lin, Yuh-Ling |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064093/ https://www.ncbi.nlm.nih.gov/pubmed/15642166 http://dx.doi.org/10.1186/bcr939 |
Ejemplares similares
-
Asymmetric bioreduction of activated alkenes to industrially relevant optically active compounds
por: Winkler, Christoph K., et al.
Publicado: (2012) -
Synthesis and Antitumor Evaluation of Novel Bis-Triaziquone Derivatives
por: Huang, Cheng Hua, et al.
Publicado: (2009) -
Bioreductive drugs and the selective induction of tumour hypoxia.
por: Bremner, J. C., et al.
Publicado: (1990) -
Bioreduction: the biological activity, characterization, and synthesis of silver
por: KORKMAZ, Nesrin
Publicado: (2020) -
Radiosensitization and Hypoxic Cell Toxicity of NLA‐1 and NLA‐2, Two New Bioreductive Compounds
por: Papadopoulou, Maria V., et al.
Publicado: (1992)